Despite all the obvious, common-sense issues (incompetence, conflict of interest, past performance) Congress is turning a blind eye to this tawdry corner of the financial services industry.
The DSMB meets periodically to review the safety results to date (Merck is blind to these data) to be certain that patients on Vytorin are not experiencing any unexpected safety issues.